{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Unconfirmed Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"No Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Complete Response(CR) is a complete disappearance of all disease with the exception of nodes. No new lesions. previously enlarged organs must have regressed and not be palpable. Bone marrow(BM) must be negative if positive at baseline. Normalization of markers. CR Unconfirmed (CRU) does not qualify for CR above, due to a residual nodal mass or an indeterminate BM. Partial Response(PR) is a 50% decrease in the sum of products of greatest diameters (SPD) for up to 6 identified dominant lesions, including spleenic and hepatic nodules from baseline. No new lesions and no increase in the size of liver, spleen or other nodes.","groups":[{"description":"Patients received IV cisplatin 25 mg/m2 days 1-4, etoposide 40 mg/m2 days 1-4, gemcitabine 1000 mg/m2 day 1 and solumedrol 250 mg days 1-4 of a 21 day cycle for 6 cycles.","id":"OG000","title":"PEGS"}],"paramType":"NUMBER","populationDescription":"All eligible patients who started protocol treatment were included in the analysis.","timeFrame":"up to 3 years or time of disease progression","title":"Response Rate","type":"SECONDARY","unitOfMeasure":"participants"}